AgomAb Therapeutics has launched its Initial Public Offering (IPO) of 12,500,000 American Depositary Shares (ADSs), each ADS representing one of its common shares, no nominal value per share, pursuant to a registration statement filed with the Securities and Exchange Commission (SEC).

Agomab expects to grant the underwriters in the offering a 30-day option to purchase up to an additional 1,875,000 ADSs at the IPO price, less underwriting discounts and commissions. The estimated IPO price is between USD 15 and USD 17 per ADS. The company has applied to list its ADSs on the Nasdaq Global Market under the symbol AGMB.

JP Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen are acting as joint book-running managers of the offering.

A registration statement on Form F-1 relating to the proposed offering has been filed with the SEC and was declared effective on 30 January, 2026.

The final terms of the offering will be disclosed in a final prospectus to be filed with the SEC.